Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olorofim for Resistant Invasive Fungal Infections
NCT03583164Phase 2Completed
- Sponsor
- F2G
- Start
- Jun 2018
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 2 trial of olorofim in invasive fungal infection (IFI), lomentosporiosis, scedosporiosis, aspergillosis, coccidioidomycosis, sponsored by F2G. Started Jun 2018; status: completed.
02
Drugs
olorofim
03
Conditions
invasive fungal infection (IFI)lomentosporiosisscedosporiosisaspergillosiscoccidioidomycosis
Beyond the preview
Go deeper on NCT03583164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583164.